Discover this podcast and so much more

Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more for just $11.99/month.

113. Best of: Recent Drug Approvals (vol. 1)! - Upadacitinib for AD - Tralokinumab for AD - Baricitinib for AA - Deucravacitinib for psoriasis - Spinosad for scabies

113. Best of: Recent Drug Approvals (vol. 1)! - Upadacitinib for AD - Tralokinumab for AD - Baricitinib for AA - Deucravacitinib for psoriasis - Spino…

FromDermasphere - The Dermatology Podcast


113. Best of: Recent Drug Approvals (vol. 1)! - Upadacitinib for AD - Tralokinumab for AD - Baricitinib for AA - Deucravacitinib for psoriasis - Spino…

FromDermasphere - The Dermatology Podcast

ratings:
Length:
70 minutes
Released:
Sep 4, 2023
Format:
Podcast episode

Description

Best of: Recent Drug Approvals (vol. 1) -
Upadacitinib for AD (from episode 59) -
Tralokinumab for AD (from episode 73) -
Baricitinib for AA (from episode 87) -
Deucravacitinib for psoriasis (from episode 93) -
Spinosad for scabies (from episode 103)
Check out our video content on YouTube:
Dermasphere Podcast - YouTube -
and VuMedi!: https://www.vumedi.com/channel/dermasphere/
The University of Utah's Dermatology ECHO: ⁠⁠https://physicians.utah.edu/echo/dermatology-primarycare -
⁠⁠Connect with us!
- Web: ⁠https://dermaspherepodcast.com/⁠
- Twitter: @DermaspherePC
- Instagram: dermaspherepodcast
- Facebook: https://www.facebook.com/DermaspherePodcast/
- Check out Luke and Michelle’s other podcast, SkinCast! ⁠https://healthcare.utah.edu/dermatology/skincast/⁠
Luke and Michelle report no significant conflicts of interest… BUT check out our friends at:
- ⁠Kikoxp.com ⁠(a social platform for doctors to share knowledge)
- ⁠https://www.levelex.com/games/top-derm⁠ (A free dermatology game to learn more dermatology!)
Released:
Sep 4, 2023
Format:
Podcast episode

Titles in the series (100)

For dermatology practitioners, Dermasphere covers the most important updates from the latest articles and research in the field. Maybe you don’t have time to read the journals—but we hope you have time to listen to a podcast about them!